Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: A randomized, 12-month double-blind extension study

Current Medical Research and Opinion

Volumn 24, Issue 11, 2008, Pages 3149-3157

  Strony, John ^a   Yang, Bo ^a   Hanson, Mary E ^a   Veltri, Enrico P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Ezetimibe; Hydroxymethylglutaryl CoA reductase inhibitor; Hypercholesterolemia; Safety; Simvastatin

Indexed keywords

EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BEDTIME DOSAGE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MYOPATHY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PLACEBOS; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 67649401873     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802426581     Document Type: Article

References (47)

1. Grundy SM, Cleeman JI, Bairey-Merz N, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-239 (Pubitemid 38924592)
2. Expert panel on detection evaluation and treatment of high blood cholesterol in adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
3. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-372
4. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v152
5. Genest J, Frohlich J, Fodor G, et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003;169:921-924
6. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14 (Suppl 2):S1-113 (Pubitemid 47339826)
7. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-2372
8. AstraZeneca. Crestor (rosuvastatin calcium) tablets [package insert]. USA ed. Wilmington, DE: AstraZeneca, 2007
9. Bristol-Myers Squibb. Pravachol (pravastatin sodium) tablets [package insert]. USA ed. Princeton, NJ: Bristol-Myers Squibb, 2007
10. Merck & Co Inc. Mevacor tablets (lovastatin) [package insert]. USA ed. Whitehouse Station, NJ: Merck & Co, Inc., 2002
11. Merck & Co Inc. Zocor (simvastatin) tablets [package insert]. USA ed. Whitehouse Station, NJ: Merck & Co. Inc., 2007
12. Novartis. Lescol (fluvastatin sodium) capsules [package insert]. USA ed. East Hanover, NJ: Novartis, 2006
13. Parke-Davis. Lipitor (atorvastatin calcium) tablets [package insert]. USA ed. New York, NY: Parke-Davis, 2007
14. Davis HR, Zhu LJ, Hoos LM, et al. Niemann-Pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004;279:33586-33592 (Pubitemid 39063007)
15. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005;102:8132-8137 (Pubitemid 40800055)
16. Davis HR, Veltri EP. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 2007;14:99-108
17. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-1097 (Pubitemid 35335597)
18. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-741 (Pubitemid 36458985)
19. Merck/Schering-Plough Pharmaceuticals. Zetia (ezetimibe) [package insert]. USA ed. North Wales, PA: Merck/Schering- Plough Pharmaceuticals, 2008
20. McKenney JM, Farnier M, Lo KW, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006;47:1584-1587
21. Jelesoff NE, Ballantyne CM, Xydakis AM, et al. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. Endocr Pract 2006;12:159-164
22. Xydakis AM, Guyton JR, Chiou P, et al. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol 2004;94:795-797 (Pubitemid 39221507)
23. Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-2026 (Pubitemid 47300401)
24. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007;99:673-680 (Pubitemid 46273307)
25. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-2134 (Pubitemid 36005898)
26. Davidson MH, Ballantyne CM, Kerzner B, et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004;58:746-755 (Pubitemid 39232318)
27. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-1091 (Pubitemid 35339435)
28. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105:2469-2475 (Pubitemid 34568966)
29. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418-424 (Pubitemid 36183559)
30. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003;24:717-728 (Pubitemid 36458984)
31. Brohet C, Banai S, Alings AM, et al. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 2005;21:571-578 (Pubitemid 40676109)
32. Cruz-Fernandez JM, Bedarida GV, Adgey J, et al. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int J Clin Pract 2005;59:619-627 (Pubitemid 44192629)
33. Farnier M, Volpe M, Massaad R, et al. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 2005;102:327-332 (Pubitemid 40854051)
34. Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587-595 (Pubitemid 40628813)
35. Ose L, Johnson-Levonas A, Reyes R, et al. A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet. Int J Clin Pract 2007;61:1469-1480 (Pubitemid 47228600)
36. Ballantyne CM, Lipka LJ, Sager PT, et al. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract 2004;58:653-658 (Pubitemid 39144578)
37. Masana L, Mata P, Gagne C, et al. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin Ther 2005;27:174-184 (Pubitemid 40462010)
38. Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004;148:447-455 (Pubitemid 39265117)
39. Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin 2007;23:767-775 (Pubitemid 46631480)
40. McKenney J, Ballantyne CM, Feldman TA, et al. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. MedGenMed 2005;7:3 (Pubitemid 41348953)
41. Lipka L, Sager P, Strony J, et al. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 2004;21:1025-1032 (Pubitemid 40075727)
42. Bennett S, Sager P, Lipka L, et al. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. J Womens Health (Larchmt) 2004;13:1101-1107
43. Parks M, Orloff D. New Drug Application Medical Reviews: Vytorin. Center for Drug Evaluation and Research; 2004 Jul 12. Report No.: NDA # 21-687
44. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-1443
45. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl. 2003;84:S207-10 (Pubitemid 36513411)
46. SHARP Collaborative Group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease - 1 year safety and biochemical efficacy. Am Soc Nutrition. 2007
47. Padial LR. Ezetimibe plus simvastatin cardiovascular outcomes study program. Expert Rev Cardiovasc Ther 2008;6:17-25